Recruiting
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer - CA125-1008
Mis à jour: 27 août, 2024 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Emplacement(s)
Recruiting
Inclusion Criteria: - Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate. - Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. - Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening - Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) Exclusion Criteria: - Participant must not have history of brain metastases. - Participant must not have impaired cardiac function or clinically significant cardiac disease. - Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment. Other protocol-defined inclusion/exclusion criteria apply
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales
